Determining the Lymphokine Activated Killer (LAK) Cytotoxicity Present in Patients Undergoing Interleukin-2 Therapy
Therapy with Interleukin-2 stimulates lymphocytes in humans to become Lymphokine-activated Killer cells (LAK). This study will determine if these killer cells are able to kill certain standard cell-lines in the laboratory.
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Lymphokine Activated Killer (LAK) Cell Activity Against Cell Lines In-vitro of LAK Generated in Vivo by Pulse Interleukin-2 Therapy|
- LAK cytotoxicity [ Time Frame: 4 months ] [ Designated as safety issue: No ]
|Study Start Date:||November 2009|
|Study Completion Date:||March 2012|
|Primary Completion Date:||December 2010 (Final data collection date for primary outcome measure)|
|patients with melanoma or kidney cancer|
Blood samples will be taken from patients undergoing outpatient Interleukin-2 therapy to measure the LAK cytotoxicity at baseline, after 1 cycle of therapy and 2 months later. The LAK cytotoxicity assay will be a standard colorimetric assay that measures lactic dehydrogenase release from lysed cells.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01068470
|United States, California|
|Loma Linda University Cancer Center|
|Beaumont, California, United States, 92223|
|Principal Investigator:||Walter Quan, MD||Loma Linda University|